Dry eye treatment improves signs and symptoms at 1 week




Wirta D, et al. Dry eye signs, symptoms and improvements in quality of life associated with AR-15512 administration. Presented at the Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver.

Disclosures: Wirta reports receiving a grant from Aerie Pharmaceuticals as the principal investigator for this study.

We have not been able to process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

DENVER – A large Phase 2b study has shown that using Aerie Pharmaceuticals’ compound AR-15512 resulted in improved tear production and dry eye symptoms at 7 days and 14 days, according to David Wirtone, MD, from the Eye Research Foundation.

The cold thermoreceptor agonist TRPM8 affects receptors in the conjunctiva, cornea and eyelid to stimulate a feeling of coldness in the eye, resulting in reflex tearing, Wirta said.

Source link

Comments are closed.